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The aim of this study is to prepare a model for the production of Newcastle disease virus (NDV) lentogenic F strain using cell
culture in bioreactor for live attenuated vaccine preparation. In this study, ﬁrstly we investigated the growth of Vero cells in several
culture media. The maximum cell number was yielded by culture of Vero cells in Dulbecco’s Modiﬁed Eagle Medium (DMEM)
which was 1.93 × 106 cells/ml. Secondly Vero cells were grown in two-litre stirred tank bioreactor by using several commercial
microcarriers. We achieved the maximum cell concentration about 7.95 × 105 cells/ml when using Cytodex 1. Later we produced
Newcastle Disease virus in stirred tank bioreactor based on the design developed using Taguchi L4 method. Results reveal that
higher multiplicity of infection (MOI) and size of cell inoculums can yield higher virus titer. Finally, virus samples were puriﬁed
usinghigh-speedcentrifugationbasedon3
∗∗(3-1)FractionalFactorialDesign.Statisticalanalysisshowedthatthemaximumvirus
titer can be achieved at virus sample concentration of 58.45% (v/v), centrifugation speed of 13729rpm, and centrifugation time
of 4 hours. As a conclusion, high yield of virus titer could be achieved through optimization of cell culture in bioreactor and
separation by high-speed centrifugation.
1.Introduction
Newcastle disease (ND), caused by Newcastle disease virus
(NDV), is reported as the most important viral disease
of poultry in the world [1]. ND has been a devastating
disease of poultry, and in many countries the disease
remains one of the major problems aﬀecting existing or
developing poultry industries. The disease can vary from
clinically inapparent to highly virulent forms, depending
on the virus strain and the host species [2]. NDV belongs
to the Avulavirus genus within the family Paramyxoviridae,
subfamily Paramyxovirinae, in the order Mononegavirales
and is designated avian paramyxovirus-1 (APMV-1). Nine
avian paramyxovirus serotypes (APMV-1 to APMV-9), of
which APMV-1 is the most economically important, have
been identiﬁed among these virus types [3]. The enveloped
virus has a negative-sense, single-stranded RNA genome
which codes for six proteins including a nucleoprotein (N),
phosphoprotein (P), matrix (M) protein, fusion (F) protein,
hemagglutinin-neuraminidase (HN) protein, and an RNA
directed RNA polymerase (L) in the 3  to 5  direction [4].
NDV isolates display a spectrum of virulence in chickens,
from a fatal to an inapparent infection [3]. Strains of NDV
are classiﬁed into three major pathotypes, depending on the
severity of disease produced in chickens. Lentogenic strains
do not usually cause disease in adult chickens and are widely
used as live vaccines in poultry industries in the United
States and other countries. Viruses of intermediate virulence
that cause respiratory disease are termed mesogenic, while
virulent viruses that cause high mortality are termed as
velogenic [5].
Until now, there is no treatment for the disease [6].
Prevention is to import birds from disease-free ﬂocks only
[7] or through vaccination that must continue throughout
the life of the bird [6]. Traditionally, ND vaccines have been
produced by growing vaccine virus strains in embryonated2 Journal of Biomedicine and Biotechnology
chicken eggs. NDV is harvested from the allantoic ﬂuid and
processed to create a vaccine. However, this procedure has
the disadvantages of being labour-intensive, time consuming
and requires large area for the incubation of eggs. Cell
cultures on the other hand are more convenient and
less expensive than eggs and also convenient to examine
microscopically for evidence of viral proliferation. However
the current titers of NDV propagated in cell cultures are
usually lower than those obtained in embryonated eggs.
Nevertheless, some manufacturers still ﬁnd it economically
feasible to use the more mechanized cell culture methodol-
ogy for producing inactivated ND vaccines [8]. Mechanism
toproduceNDVvaccineiskeepdiagnosed andupdated time
by time to improve the production.
Cell substrate systems that have been identiﬁed to be able
t op r o d u c eN D Va r eV e r o( A f r i c a nG r e e nM o n k e y ) ,C E F
(chicken embryonic ﬁbroblasts), and DF-1 (continuous cell
line derived from CEF) [4, 9, 10] .T h e s ec e l l sa r ea n c h o r a g e
dependent where they require surface of a matrix to facilitate
cell growth. Microcarrier technology which was introduced
by Van Wezel for culturing anchorage-dependent cells in
suspension is easily applied in stirred tank bioreactors; it
is scalable, and it is able to produce high number of cells
per volume ratio [11]. Microcarrier cell culture system oﬀers
many advantages over conventional ﬂasks or bottle cultures
in growing anchorage-dependent cells and has been used
for the industrial manufacture of polio, rubella, rabies,
inﬂuenza, and foot-and-mouth disease (FMD) vaccines [12–
15].
This work addresses the production of F strain of NDV
in cultured Vero cells. To achieve high virus titer we have
determinedthemostsuitableculturemediaandmicrocarrier
which are able to yield the highest cell number. Later we
investigated the eﬀect of diﬀerent sizes of cell inoculum,
serum concentrations during virus growth phase, and mul-
tiplicity of infection (MOI) on the virus titer. We have
also optimized the operating condition for purifying NDV
using high-speed centrifugation method. All these results
constitute valuable information on the development of a
large-scale microcarrier cell culture process for producing
NDV vaccine.
2.Methodology
2.1. Cell Line. Vero cells obtained from the Veterinary
Research Institute (Ipoh, Malaysia) were used in this study.
2.2. Virus Strain. Lentogenic F strain of NDV adapted to
grow in Vero cells and provided by Universiti Putra Malaysia
(Selangor, Malaysia) was used throughout the study.
2.3. Culture Media and Chemicals. DMEM, RPMI, MEM,
and L-15 media were supplied by Invitrogen (Glasgow,
UK). RPMI without phenol red media was supplied by
Mediatech (Virginia, USA). Fetal bovine serum (FBS) and
antibiotic (Penstrep) were supplied by Invitrogen (Glasgow,
UK). Accutaseenzyme was provided by Innovative Cell (Cal-
ifornia, USA). Cytodex 1 and Cytodex 3 microcarriers were
obtained from Amersham Biosciences (Uppsala, Sweden).
Hillex and Plustic Plus microcarriers were obtained from
SoloHill(Michigan,USA).Allotherchemicalswereobtained
f r o mS i g m a( S t .L o u i s ,U S A ) .
2.4. Microcarrier Preparation. Cytodex 1, Cytodex 3, Hillex,
and Plustic Plus microcarriers were prepared and sterilized
according to manufacturer’s instructions. For Cytodex 1 and
Cytodex 3, the microcarriers were swollen with Ca2+,M g 2+-
free PBS twice and autoclaved at 115◦C for 15 minutes while
for Hillex and Plustic Plus microcarriers, they were washed
withdeionizedwaterandautoclavedat121◦Cfor30minutes.
All microcarriers were washed and incubated with culture
media prior to use.
2.5. Growth in Static Culture. V e r oc ell sw e r egr o wni ns e ru m
containing medium as described by Freshney [16]. Static
cultures of cells were carried out under these conditions: a
seedingdensityof1×105 cells/cm2,temperatureof37 ◦C,and
5% concentration of CO2.
2.6. Bioreactor Cultures. Cultures were performed in a 1.5L
bioreactor (Infors HT, Switzerland) with one-litre working
volume and equipped with an elephant ear impeller. For
starting the microcarrier cultures, the cells were detached
from T-ﬂasks using Accutase enzyme and incubated in the
reactor in the presence of the microcarriers. The culture
was seeded with 5 × 104 cells/mL and was continuously
agitated at 70rpm. The starting volume was equal to
1L. During cell culture proliferation phase, the following
conditions were applied: pH set at 7.2 (regulated by injec-
tion of CO2 and addition of 1M HCL and 1M NaOH),
pO2 maintained at 30% air-saturation by injecting air
when required, temperature at 37◦C, and agitation rate at
70rpm.
For NDV production phase, pH was maintained at 7.4,
pO2 at 30% air-saturation, agitation rate at 100rpm, and
temperature at 37◦C. Once cell density reached maximum,
cells were washed with PBS. Later cells were infected with
NDV according to the designed levels by inoculation of virus
in DMEM supplemented with trypsin. After 1 hour of cell
infection, more DMEM was added until the working volume
reaches one litre and the stirring was restarted. Samples
were taken daily to determine the following factor: cell con-
centration, cell viability, and virus titer. Cell concentration
was counted by counting cell released after trypsinization
[17].
2.7. Speciﬁc Growth Rate and Doubling Time. Calculation of
s p e c i ﬁ cg r o w t hr a t e( µ) using the formula of Scheirer and
Merten [18]w a su s e d :
µx =

lnXn −lnXn−1
tn −tn−1

,( 1 )
where X represents the viable cell density per mL, and t the
time points ofsampling expressedinhours; nandn−1stand
for two succeeding sampling points.Journal of Biomedicine and Biotechnology 3
Doubling time (tD) is given by the formula:
td =

ln2
µ

. (2)
2.8. High-Speed Centrifugation. Harvested virus sample was
diluted using phosphate buﬀer saline (PBS) into three
diﬀerent concentrations: 25%, 50%, and 100% (v/v). About
1.8g of Polyethylene Glycol 600 (PEG) was added into 40mL
of each virus sample and stirred in a sealed centrifuge tube at
4◦C for 4 hours. After 4 hours, samples were centrifuged at
4◦C at designed speed and time. After that the pellet for each
samplewasresuspendedin0.4mLPBSandtransferredintoa
centrifuge tube. The suspended pellet was later sonicated for
30 seconds until aggregates were disrupted. The debris was
then spinned out at 14000rpm for 10 minutes. HA test was
performed to determine the ﬁnal titer.
2.9. Haemagglutination Assay (HA) Test. The haemaggluti-
nation assay (HA) method described by Grimes [19]w a s
used. Using a 96-well V-shaped microtiter plate, 50µl PBS
was added from wells 2A–12A. One hundred microlitres of
v i r u ss a m p l ew a sa d d e dt ow e l l1 At ow h i c h5 0µlo fi tw a s
serially diluted up to well 11A. Fifty microlitres of 1% red
bloodcell(RBC)wasaddedtoallwells.AgglutinationofRBC
was observed in wells containing the virus while clumping
of RBC was seen in wells containing no virus. Dilution of
the last well showing agglutination gave the titer of the virus
sample. Haemagglutination units were multiplied by 20 and,
therefore, expressed per mL as HAU/mL.
2.10. TCID50 Assay. Fifty percent tissue culture infectious
dose (TCID50) assay was carried out in 96-well ﬂat shaped
microtiter plates. Plates were seeded with Vero cells such that
conﬂuence was reached in 2-3 days. Vero cells were grown
in DMEM media containing 10% FBS and grown at 37◦C,
5% CO2. Appropriate dilutions of each virus were prepared
in DMEM medium and 100µl of each dilution was added to
eachwell.Plateswereincubatedat37◦Cfor30–60minbefore
100µL of DMEM was added to each well. The plates were
then incubated for 4 days until the CPE eﬀect was appeared.
The log TCID50/mL calculation was based on the Reed and
Muench [20] formula.
2.11.Taguchi’sOrthogonalDesign. TaguchiL4arraywasused
to design NDV production in bioreactor experiments. Three
factors that were chosen to be manipulated in four runs of
experiment are size of cell inoculums, serum concentration
during virus production phase, and multiplicity of infection,
MOI. The levels of the factors studied and the layout of the
L4 Taguchi’s orthogonal array are shown in Table 1.
2.12. Fractional Factorial Design. 3∗∗(3-1) Fractional Fac-
torial Design was used to assist high-speed centrifugation
experiments. Three factors that were chosen to be manipu-
lated in nine runs of experiment are sample concentration,
speed, and time. The levels of the factors studied and the
layout of the fractional factorial design are shown in Table 2.
Table 1: The L4 array Taguchi layout.
Level
12
Cell inoculum (A)( c e l l s / m L ) 0 .5 ×105 1.0 ×105
Serum concentration(B)( % ) 0 . 5 2
MOI (C)0 . 2 2
Table 2: 3∗∗(3-1) Fractional Factorial Design for High-Speed
Centrifugation.
Level
−10 1
Sample conc.(A) (%) 25 50 100
Speed (B) (rpm) 6400 12800 19200
Time (C) ( h ) 481 2
3. Results and Discussion
3.1. Selecting Culture Media for Growth of Vero Cells. Four
diﬀerent culture media, MEM, DMEM, L-15, and RPMI
1640, have been used to culture Vero cells in T-ﬂasks in order
to determine which medium has the capability to yield the
maximum cell concentration. As shown in Figure 1,c u l t u r e
of Vero cells in DMEM has generated the maximum cell
concentrationwhichwas1.93×106 cells/mL.Thisisfollowed
by culture of Vero cells in Leibovitz’s L-15 media which has
yielded 1.5 × 106 cells/mL, MEM (1.42 × 106 cells/mL), and
RPMI (7.55 ×105 cells/mL).
Growth of Vero cells in DMEM was in lag phase from 0h
until40h.Startingfrom40h,thecultureenteredexponential
phase and reached the maximum cell concentration at 56h.
Once reached the maximum, cell concentration dropped
continuously until the end of the culture. From growth
kinetic aspect, again culture of Vero cells in DMEM had
achieved the best result where the speciﬁc growth rate µx
and doubling time td recorded were 0.052h−1 and 13.11
hours. This is followed by L-15 with µx of 0.042h−1 and td
of 16.38 hours, MEM (µx = 0.041 and td = 16.72h), and
RPMI (µx = 0.036 and td = 19.20h). Based on these results,
DMEM was selected to be used in further stages of the study
because it has the best performance in terms of maximum
cell concentration yielded and also growth kinetic.
DMEM has more glucose and glutamine concentration
than any other medium does thereby sustaining the growth
of cells for a longer period. Glucose and glutamine are the
most vital nutrients in media providing carbon and nitrogen
source, respectively, thus vital for cellular metabolism [21].
In addition, DMEM is also reported as able to support the
growth of cells to much higher densities compared to many
other culture media because the concentrations of certain
essential amino acids and vitamins are several fold greater
in DMEM than in the other media.
3.2. Selecting Microcarrier for Growth of Vero Cells. At w o -
litre bench-top bioreactor was used to culture Vero cells on
four diﬀerent types of microcarrier to determine which type4 Journal of Biomedicine and Biotechnology
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Figure 1: Comparison of Vero cell growth in four diﬀerent culture
media. All media were supplemented with 10% fetal bovine serum
(FBS).
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Figure 2: Comparison of Vero cell growth on diﬀerent types of
microcarrier in a 2L stirred tank bioreactor.
of microcarrier can best support the growth of Vero cells in
a nonstatic culture. Four types of commercial microcarriers
that were selected for this purpose were Cytodex 1, Cytodex
3, Hillex, and Plastic Plus (PP). Figure 2 shows the growth
proﬁle of Vero cells on all types of microcarrier. From the ﬁg-
ure it can be seen that the growth of Vero cells on Cytodex 1
microcarrier yielded the maximum cell concentration which
was 7.95 × 105 cells/mL. This is followed by culture of Vero
cells on Cytodex 3 which has yielded 7.40 × 105 cells/mL,
Hillex (1.05 × 105 cells/mL), and Plastic Plus (PP) (1.00 ×
105 cells/mL). Cell attachment on each type of microcarrier
could be clearly observed by microscopic examination as
shown in Figures 3(a)–3(d).
In terms of growth kinetic aspect, the best result was
shown by Vero cell culture on Cytodex 3 microcarriers which
had the speciﬁc growth rate µx and doubling time td of
0.052h−1 and 13.11 hours. This is followed by Cytodex 1
with µx of 0.035h−1 and td of 20.04 hours, Hillex (µx =
0.018 and td = 37.36h), and Plastic Plus (PP) (µx = 0.011
and td = 64h). Although Cytodex 3 microcarriers had
the highest speciﬁc growth rate and the lowest doubling
(a) (b)
(c) (d)
Figure 3:CellattachmentofVerocellsonfourdiﬀerentmicrocarri-
ers viewed under inverted light microscope at magniﬁcation of 20x:
(a) Cytodex 1; (b) Cytodex 3; (c) Hillex; (d) Plastic Plus (PP).
time, the diﬀerences compared to Cytodex 1 microcarriers
were not signiﬁcant as compared to the other two types of
microcarriers. Therefore Cytodex 1 can be regarded as the
optimum for supporting cell growth and was selected to be
used in later stages of the study.
Both Cytodex 1 and Cytodex 3 microcarriers pro-
duced by Amersham Biosciences are made from dextran
while Hillex and Plastic Plus (PP) microcarriers which
are produced by SoloHill Inc. are made from polystyrene
material. Dextran is a degradable material that allows cells
to be harvested easier compared to polystyrene which is a
nondegradable material [22]. This fact may partially explain
for lower cell concentration obtained when using Hillex and
PlasticPlus(PP)polystyrenemicrocarrierscomparedtoboth
Cytodex microcarriers.
Another observation was the concentration of micro-
carrier used. In this study, Cytodex 1 and 3 microcarriers
were used at a concentration of 3g/l while Hillex and
Plastic Plus (PP) microcarriers were used at 14g/l and
20g/l, respectively, as recommended by the manufacturers.
Mendonc ¸a and Pereira [23] and Julien [24] reported that
high concentrations of microcarriers in bioreactor culture
reduced the ability of cells to attach due to increased shear
stress emanating from collisions between microcarriers.
3.3. Vero Cell Culture in Bioreactor for NDV Production. To
optimize production of NDV in the bioreactor, the eﬀects
of the following three factors have been investigated: cell
inoculum size (factor A), serum concentration during virus
replication phase (factor B), and multiplicity of infection,
MOI (factor C). These factors were manipulated in four runs
of experiment that was designed using Taguchi L4 model.
Figures4(a)–4(d)showthegrowthproﬁleofVerocellson
Cytodex 1 microcarriers and the kinetic of NDV replication.
In all four runs, virus was infected to the culture at 72h.
From the ﬁgure, it can be observed that similar behaviour
was exhibited in all four runs where viable cell concentration
dropped sharply after infection and continues to decreaseJournal of Biomedicine and Biotechnology 5
Table 3: NDV Production result (HA and TCID50).
Run Cell inoculums (cells/mL) (A) Serum conc. (%) (B)M O I ( C) Max. HA titer (HAU/mL) Max. infectivity titer (tcid50/mL)
11 .0 ×105 0.5 2 10240 4.79 ×107
20 .5 ×105 2 2 10240 4.67 ×107
31 .0 ×105 2 0.2 1280 3.22 ×107
40 .5 ×105 0.5 0.2 640 3.08 ×107
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Figure 4: Growth of Vero cells on Cytodex 1 microcarrier and production of NDV: (a) cell inoculums: 1.0 × 105 cells/mL, serum
concentration: 0.5%, MOI: 2.0; (b) cell inoculums: 0.5 × 105 cells/mL, serum concentration: 2.0%, MOI: 2.0; (c) cell inoculums: 1.0 ×
105 cells/mL,serumconcentration:2.0%,MOI:0.2;(d)cellinoculums:0.5×105 cells/mL,serumconcentration:0.5%,MOI:0.2.(↑)indicates
cell infection.
until the end of the culture period. Figure 5(a)–5(d) shows
themicroscopicexaminationofVero’scellgrowthbeforeand
after NDV infection in 2-litre stirred tank bioreactor.
Table 3 shows the maximum HA titer and maximum
infectivity titer obtained for each run conducted according
to the L4 Taguchi array. The lowest virus yields were
reached during Run 4. In these conditions, maximum HA
titer achieved was 640HAU/mL. On the other hand, the
maximum HA titer was achieved during Run 1 and Run 2
and was equal to 10240HAU/mL. Run 1 also achieved the
maximum infectivity titer which was 4.79 ×107 tcid50/mL.
The calculation of the variance for each factor studied
shows that the lowest value was obtained by factor B (serum
concentration during virus replication phase). This indicates
that this factor did not have a signiﬁcant eﬀect on the virus
titer. Thus it was neglected and its eﬀect was considered as
residual error (R). Analysis of variance and ANOVA table
are presented in Table 4. As shown in the table, MOI was
the most signiﬁcant factor in yielding NDV as it has the
lowest P value and less than .05. The analysis also suggests
that yield of NDV can be increased when cell inoculum
and MOI are increased. For predicting the optimal values of
NDVproduced,alinearmodelwasﬁttedtotheexperimental
results for the NDV yield by the Design Expert software. The
model developed is as follows:
Y

Virus titer,
HAU
mL

=− 551.1+0 .0064A + 5155.6C,
(3)
where the NDV production as yield (Y) is a function of cell
inoculum (A) and multiplicity of infection, MOI (C).
At the model level, multiple correlation coeﬃcient R
and the determination coeﬃcient R2 measure for the esti-
mation of the regression equation. The correlation between6 Journal of Biomedicine and Biotechnology
Table 4: Analysis of variance (ANOVA) for Taguchi L4 model.
Source Sum of squares F value P value
Model 8.622 ×107 421 .0344
Cell inoculum, A 1.024 ×105 1 .5000
MOI, C 8.612 ×107 841 .0219
(a) (b)
(c) (d)
Figure5:MonitoringofCytodex1microcarriersduringcellgrowth
and NDV production phases of Vero cells grown in a 2L bioreactor.
Cells were observed with an inverted light microscope without
staining: (a) day 0, (b) day 2, (c) day 3, and (d) 2 day post infection.
the experimental and predicted values is better when the
value of R is closer to 1. In this experiment, the values
of R and R2 were 0.999 and 0.998, respectively, for the
NDV production. These indicates high degree of correlation
between the experimental and the predicted values. The
value of R2 indicates that 99.8% of the factors size of
cell inoculum and multipilicity of infection contribute very
positively to the response. The value of R2 is also a measure
of ﬁt of the model and it can be mentioned that only about
0.2%ofthetotalvariationswerenotexplainedbyNDVyield.
The value of the adjusted determination of coeﬃcient was
also very high (99.64%) which indicates a high signiﬁcance
of the model.
3.4. High-Speed Centrifugation. Harvested virus samples
were puriﬁed using high-speed centrifugation method. To
optimize the puriﬁcation, the eﬀects of the following three
factors have been investigated: sample concentration (factor
A), centrifugation speed (factor B), and centrifugation time
(factor C). These factors were manipulated in nine runs
of experiment that was designed using 3∗∗(3-1) Fractional
Factorial design.
Table 5 shows the result of all nine runs of experiment.
Among all runs, the maximum virus titer was achieved
during Run 6 where the maximum virus titer produced was
5120HAU/mL. The results also reveal that centrifugation
speed of 6400rpm always yielded the lowest virus titer. This
suggests that this speed is not suﬃcient for the virus to settle
down.
From Table 6, it was observed that the most signiﬁcant
factor is the square term of sample concentration (A2)w h i c h
Table 5: Result for high-speed centrifugation.
Run Sample
conc. (%)
Speed (rpm) Time (h) Virus titer
(HAU/mL)
1 25 12800 12 2560
2 25 19200 8 1280
3 25 6400 4 160
4 50 6400 12 1280
5 50 19200 4 2560
6 50 12800 8 5120
7 100 19200 12 640
8 100 12800 4 320
9 100 6400 8 160
Table 6: Analysis of variance (ANOVA) for 3∗∗ (3-1) Fractional
Factorial model.
Source Sum of squares F value P value
Model 19421866 3.78072977 .039909
Sample conc., A 1382400 1.614618 .331650
Speed, B 1382400 1.614618 .331650
Time, C 345600 0.403654 .590203
A2 7509943 8.771476 .097601
B2 5467022 6.385382 .127366
C2 1742222 2.034884 .289843
has the least P value of .097601. For predicting the optimal
values of NDV titer produced, a second-order polynomial
model was ﬁtted to the experimental results by Statistica
software. The model developed is as follows:
Y

Virus titer,
HAU
mL

=− 12355.6 + 184.5(A) −1.6

A2
+1 .1(B) −0.0

B2
+ 993.3(C)
−58.3

C2
,
(4)
where the NDV titer produced as yield (Y)i saf u n c t i o n
of sample concentration (A), centrifugation speed (B), and
centrifugation time (C).
Correlation coeﬃcient R and the determination coeﬃ-
cient R2 obtained in this experiment are 0.9586 and 0.9189,
respectively. Value of R that is close to 1 indicates that
the correlation between the experimental values of this
experiment with the predicted values is high. The software
also deduced that the maximum NDV titer can be produced
when the sample concentration is 58.45%, centrifugation
speed is 13729.03rpm, and centrifugation time is 8.51 hours.
4. Conclusion
In this study, DMEM was found to be the most suitable
culture medium for growing Vero cells when compared
to Leibovitz’s L-15, RPMI 1640, and MEM. Also among
severaltypesofmicrocarrierthathavebeentested, Cytodex 1Journal of Biomedicine and Biotechnology 7
stood out as the best substrate for cells to adhere and
grow in nonstatic culture. From analysis using statistical
software like Design Expert and Statistica, it has been
found that NDV production in 2L stirred tank bioreactor
can be improved when size of cell inoculums and MOI
is increased. Also it has been analyzed that the optimum
conditions to purify NDV using high-speed centrifugation
are sample concentration of 58.45%, centrifugation speed of
13729.03rpm, and centrifugation time of 8.51 hours.
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